Related Experiment Video
Updated: Jul 4, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Design and synthesis of 4-HPR derivatives for rhabdoid tumors
Bhaskar C Das1, Melissa E Smith, Ganjam V Kalpana
1Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. bdas@aecom.yu.edu
Abstract:
Rhabdoid tumors (RTs) are aggressive pediatric malignancies with poor prognosis that arise due to loss of the hSNF5/INI1 tumor suppressor. Molecular studies indicate that cyclin D1, a downstream effector of INI1 is up regulated in RT, and is essential for this tumor formation. Previously we demonstrated that 4-HPR, a synthetic retinoid that targets Cyclin D1, is a potential chemotherapeutic agent for RT. To facilitate further chemical development of this retinoid, and to determine its active moiety, we synthesized small chemical libraries of 4-HPR and tested their cytotoxic effect on RT cells. We synthesized 4-HPR (1) and the derivatives (5a-5n) starting from retinoic acid. First, retinoic acid was converted to acid chloride derivatives, then in the presence of DMF, base, and aniline derivatives, we synthesized the corresponding 4-hydroxy phenyl amine derivatives (5a-5n). This procedure gave 70-90% yield. Then, the 4-HPR derivatives were tested for their ability to inhibit RT cells using an in vitro cell survival assay. We found that the 4-hydroxy group at para-position is essential for cytotoxic activity against RT cells. Furthermore, we identified a few derivatives of 4-HPR with higher cytotoxic potencies than 4-HPR. In addition, we demonstrate that either chloro, fluoro or iodo derivatives at meta-position of phenyl ring retain the cytotoxic activity. Interestingly, substitution of iodo-moiety at meta-position (5j) substantially increased the efficacy (IC(50) approximately 3muM, Fig. 1D). These results indicate that chemical modification of 4-HPR may result in derivatives with increased therapeutic potential for RTs and that halogen substituted 4-HPR that retain the activity can be synthesized for further therapeutic and diagnostic use.
Insights
Researchers modified 4-HPR, a synthetic retinoid, to create new treatments for aggressive pediatric rhabdoid tumors (RTs). The 4-hydroxy group is crucial for activity, and halogen substitutions, particularly iodine, enhance efficacy against RT cells.
Area of Science:
- Oncology
- Pediatric Oncology
- Medicinal Chemistry
Background:
- Rhabdoid tumors (RTs) are aggressive pediatric cancers linked to hSNF5/INI1 loss.
- Cyclin D1, a downstream INI1 effector, is upregulated in RTs and essential for tumor growth.
- 4-HPR, a synthetic retinoid targeting Cyclin D1, shows potential as a chemotherapeutic agent for RTs.
Purpose of the Study:
- To synthesize and evaluate 4-HPR derivatives for enhanced anti-RT activity.
- To identify the essential structural features of 4-HPR for its cytotoxic effects.
- To explore potential therapeutic and diagnostic applications of modified 4-HPR.
Main Methods:
- Synthesis of 4-HPR and derivatives (5a-5n) from retinoic acid.
- Chemical modifications included creating acid chloride derivatives and reacting them with aniline derivatives.
- In vitro cell survival assays were used to test the cytotoxic effects of synthesized compounds on RT cells.
Main Results:
- The 4-hydroxy group at the para-position of 4-HPR is essential for cytotoxic activity against RT cells.
- Several 4-HPR derivatives exhibited higher cytotoxic potency than the parent compound.
- Halogen substitutions (chloro, fluoro, iodo) at the meta-position retained cytotoxic activity, with iodo-substitution (5j) significantly increasing efficacy (IC50 ≈ 3µM).
Conclusions:
- Chemical modification of 4-HPR can yield derivatives with improved therapeutic potential for RTs.
- Halogenated 4-HPR derivatives maintain cytotoxic activity and can be developed for therapeutic and diagnostic purposes.
- Further development of these modified retinoids may lead to more effective treatments for pediatric rhabdoid tumors.
